Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrapone for cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome
2019-002008-41Phase 4Active
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of metyrapone in Cushing's syndrome and hypertension (HTN), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Primary endpoint: change in antihypertensive medication burden at 12 months. Started Dec 2020; status: active.
02
Drugs
metyrapone
03
Conditions
Cushing's syndromehypertension (HTN)
Beyond the preview
Go deeper on 2019-002008-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002008-41.